Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Six RNAi-Related Patent Applications: Jan 3, 2008

Title: Cancer Therapeutic
Number: 20070298445
Filed: March 5, 2007
Lead Inventor: Douglas Boyd, MD Anderson Cancer Center
The patent application, its abstract states, claims “methods for the delivery of a [short interfering nucleic acid] to a cell via a liposome. In certain embodiments, the siNA may bind to a nucleotide sequence encoding ZNF306 protein. These methods may be used to treat a disease, such as cancer.
“One example of a composition [covered by the application] is a composition comprising a siNA component that binds to a nucleotide sequence encoding ZNF306 protein and a lipid component,” the abstract adds. “One example of a method is a method of treating cancer.”

Title: microRNA Biomarkers for Human Breast and Lung Cancer
Number: 20070299030
Filed: April 2, 2007
Lead Inventor: Ethan Dmitrovsky, University of Copenhagen
The invention, the patent application’s abstract states, “relates to novel molecular markers for diagnosis and classification of human breast cancer and lung cancer.”

Title: siRNA Targeting Vacuolar ATPase
Number: 20070299253
Filed: March 30, 2007
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to vacuolar ATPase.”

Title: Temporal Regulation of Gene Expression by microRNAs
Number: 20070300329
Filed: June 26, 2007
Lead Inventor: Edwards Allen, Monsanto
“This invention provides molecular constructs and methods for the temporally specific control of gene expression in plants or in plant pests or pathogens,” according to the patent application’s abstract. “More specifically, this invention provides plant miRNA genes having novel circadian expression patterns that are useful for designing recombinant DNA constructs for temporally specific expression of at least one gene. Also provided are non-natural transgenic plant cells, plants, and seeds containing in their genome a recombinant DNA construct of this invention.”

Title: Methods for Quantitating Small RNA Molecules
Number: 20070292878
Filed: July 18, 2007
Inventor: Christopher Raymond, Rosetta Inpharmatics (Merck)
“In one aspect, the present invention provides methods for amplifying a microRNA molecule to produce DNA molecules,” the patent application’s abstract states. “The methods each include the steps of: using primer extension to make a DNA molecule that is complementary to a target microRNA molecule; and using a universal forward primer and a reverse primer to amplify the DNA molecule to produce amplified DNA molecules. In some embodiments of the method, at least one of the forward primer and the reverse primer comprise at least one locked nucleic acid molecule.”

Title: Compositions and Methods for Delivery of Double-Stranded RNA
Number: 20070293449
Filed: June 20, 2007
Lead Inventor: Kunyuan Cui, Nastech Pharmaceutical (MDRNA)
The patent application, its abstract states, claims “pharmaceutical compositions and methods of use of a composition containing a double-stranded RNA, cationic lipids, non-cationic lipids, and lipophilic delivery-enhancing compounds.”

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.